Definiens scooped up by AstraZeneca
This article was originally published in Clinica
Executive Summary
Image analysis and tumor biomarker specialist Definiens is being bought AstraZeneca as it consolidates its position in oncology R&D. AstraZeneca's MedImmune unit will acquire 100% of Definiens' shares for $150m upfront and make additional predetermined milestone payments.